Stopping Overdoses of Fentanyl Analogues Act

Bill Number

H.R. 1064

Origin Chamber

House

Congress

119th Congress, Session 1

Policy Area

Crime and Law Enforcement

Status

Introduced

Latest Action

2025-02-06: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Last Updated

2025-04-24T15:50:04Z

AI-Generated Summary

Purpose

The "Stopping Overdoses of Fentanyl Analogues Act" aims to combat the fentanyl overdose crisis by classifying a broad range of fentanyl-related substances as Schedule I controlled substances under the Controlled Substances Act (CSA). Schedule I drugs are those with high potential for abuse and no accepted medical use, making them illegal to manufacture, distribute, or possess without authorization. This legislation targets synthetic variations of fentanyl to close loopholes that allow new analogues to evade existing drug laws.

Key Provisions

• Addition to Schedule I: Amends Section 202(c) of the CSA to include in Schedule I any material, compound, mixture, or preparation containing fentanyl-related substances, including their salts, isomers (chemically similar variants), and salts of isomers.
• Definition of Fentanyl-Related Substances: These are substances structurally related to fentanyl through one or more modifications, such as:
• Replacing the phenyl portion of the phenethyl group with any single-ring (monocyclic) structure, which may be further substituted.
• Adding groups like alkyl (carbon chains), alkenyl (unsaturated carbon chains), alkoxy, hydroxy, halo (halogen like chlorine), haloalkyl, amino, or nitro to the phenethyl group or piperidine ring (a key part of fentanyl's structure).
• Replacing the aniline ring with any aromatic single-ring structure, possibly substituted.
• Replacing the N-propionyl group with another acyl group (a type of organic acid derivative).
• Penalties: Fentanyl-related substances are automatically treated as analogues of a specific fentanyl compound (N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl] propanamide) for penalty purposes under CSA Section 401(b)(1) (trafficking penalties) and the Controlled Substances Import and Export Act Section 1010(b). This applies without needing to prove the substance meets the standard CSA definition of a "controlled substance analogue" (a substance chemically similar to a scheduled drug and intended to mimic its effects).
• Effective Date: The Act takes effect one day after its enactment into law.

Significant Changes to Existing Law

• Broadens Scheduling: Previously, the CSA scheduled specific fentanyl analogues individually, requiring the Drug Enforcement Administration (DEA) to identify and list new variants as they emerged. This bill adds a catch-all category for fentanyl-related substances based on structural modifications, allowing automatic inclusion without case-by-case scheduling.
• Simplifies Prosecution: Removes the need to prove that a substance qualifies as an analogue under CSA Section 102, which requires evidence of chemical similarity and intent to replicate effects. This streamlines enforcement for trafficking, importation, and exportation offenses, potentially leading to faster convictions and harsher sentences (e.g., up to life imprisonment for large-scale trafficking).

Potential Impacts

• On Government Agencies: Enhances the DEA's and law enforcement's ability to regulate and prosecute fentanyl variants more efficiently, reducing administrative burdens in scheduling new drugs. It may increase caseloads for federal courts due to easier application of penalties.
• On Citizens: Increases legal risks for individuals possessing, manufacturing, or distributing these substances, even if they are novel variants not previously listed. This could deter illicit production but may also affect legitimate research or medical uses if exemptions are not clearly defined. Public health benefits include potentially reducing overdose deaths by curbing availability of these highly potent opioids.
• On International Relations: Strengthens U.S. controls on fentanyl imports and exports, which could influence bilateral agreements with countries like China and Mexico (major sources of fentanyl precursors). It may support international efforts to combat global opioid trafficking but could complicate trade in legitimate chemicals used in pharmaceuticals.

Main Stakeholders Affected

• Law Enforcement and Prosecutors: Benefit from simplified legal processes for charging and sentencing.
• Drug Enforcement Administration (DEA) and Health Agencies: Gain tools for faster regulation, aiding overdose prevention efforts by the Centers for Disease Control and Prevention (CDC) and similar bodies.
• Individuals and Communities: Those involved in the opioid crisis, including users, traffickers, and overdose victims' families; higher penalties may impact underserved communities disproportionately affected by drug enforcement.
• Pharmaceutical and Research Industries: Could face restrictions on handling structurally similar compounds, requiring careful compliance to avoid unintended violations.
• International Partners: Governments and organizations involved in drug control, such as the United Nations Office on Drugs and Crime.

Notable Legal, Constitutional, or Political Implications

• Legal: Expands the scope of Schedule I without the traditional DEA rulemaking process, potentially raising questions about due process for substances that might have emerging medical value. However, it aligns with the CSA's analogue provisions to address rapidly evolving synthetic drugs.
• Constitutional: Does not directly challenge constitutional rights but could invite scrutiny under the Fifth Amendment (due process) if broadly applied to untested substances, or the Eighth Amendment if penalties are seen as disproportionately severe for analogues.
• Political: Reflects bipartisan concern over the opioid epidemic, with the bill's introduction signaling urgency in Congress. It may influence future drug policy debates, balancing public health goals against criticisms of over-criminalization or impacts on civil liberties. The memorial naming (Archie Badura) highlights personal stories driving reform.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Fitzgerald, Scott [R-WI-5]

Recent Actions

• 2025-02-06: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-02-06: Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
• 2025-02-06: Introduced in House
• 2025-02-06: Introduced in House

Bill Versions

• Stopping Overdoses of Fentanyl Analogues Act — issued 2025-02-06 — PDF (3 pages)